Stock GLENMARK GLENMARK PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-26 am EDT 		5-day change 1st Jan Change
1,079 INR -0.09% Intraday chart for Glenmark Pharmaceuticals Limited +5.16% +26.39%
Apr. 25 Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 MT
Apr. 01 Glenmark Pharmaceuticals Limited Announces Board Changes CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 182,619 58,084 131,124 124,718 131,124 304,580 - -
Enterprise Value (EV) 1 212,024 91,837 162,310 150,223 162,699 324,424 301,500 293,275
P/E ratio 20.5 x 7.49 x 13.5 x 13.2 x 44.1 x 42.6 x 25 x 19.2 x
Yield 0.31% 1.21% 0.54% 0.57% 0.54% 0.21% 0.26% 0.29%
Capitalization / Revenue 1.85 x 0.55 x 1.2 x 1.01 x 1.01 x 2.51 x 2.17 x 1.95 x
EV / Revenue 2.15 x 0.86 x 1.48 x 1.22 x 1.25 x 2.67 x 2.15 x 1.88 x
EV / EBITDA 11.8 x 5.41 x 7.79 x 6.47 x 7.14 x 25.2 x 12.5 x 10.1 x
EV / FCF 244 x 19.9 x 45.5 x 47.2 x 923 x 16.1 x 46.6 x 30.8 x
FCF Yield 0.41% 5.02% 2.2% 2.12% 0.11% 6.2% 2.15% 3.24%
Price to Book 3.05 x 0.96 x 1.86 x 1.37 x 1.38 x 2.88 x 2.55 x 2.27 x
Nbr of stocks (in thousands) 282,168 282,168 282,168 282,168 282,168 282,188 - -
Reference price 2 647.2 205.8 464.7 442.0 464.7 1,079 1,079 1,079
Announcement Date 5/29/19 6/26/20 5/28/21 5/27/22 5/19/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 98,655 106,410 109,439 123,409 129,901 121,436 140,342 156,218
EBITDA 1 17,939 16,981 20,844 23,203 22,784 12,869 24,151 28,995
EBIT 1 14,254 12,809 16,408 18,336 16,671 7,400 18,277 22,373
Operating Margin 14.45% 12.04% 14.99% 14.86% 12.83% 6.09% 13.02% 14.32%
Earnings before Tax (EBT) 1 12,580 10,961 13,825 14,412 8,685 -206.1 18,250 23,369
Net income 1 8,917 7,760 9,701 9,936 2,972 33,363 11,127 14,861
Net margin 9.04% 7.29% 8.86% 8.05% 2.29% 27.47% 7.93% 9.51%
EPS 2 31.60 27.50 34.38 33.40 10.53 25.35 43.10 56.30
Free Cash Flow 1 870 4,610 3,565 3,185 176.3 20,118 6,472 9,512
FCF margin 0.88% 4.33% 3.26% 2.58% 0.14% 16.57% 4.61% 6.09%
FCF Conversion (EBITDA) 4.85% 27.15% 17.1% 13.73% 0.77% 156.33% 26.8% 32.81%
FCF Conversion (Net income) 9.76% 59.41% 36.74% 32.06% 5.93% 60.3% 58.17% 64.01%
Dividend per Share 2 2.000 2.500 2.500 2.500 2.500 2.318 2.830 3.168
Announcement Date 5/29/19 6/26/20 5/28/21 5/27/22 5/19/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 27,868 28,599 29,649 31,474 31,734 30,191 27,773 33,752 34,639 33,737 34,016 35,822 34,919 33,001
EBITDA 1 5,301 5,234 5,736 5,902 5,148 4,634 4,726 6,216 6,202 6,050 5,866 6,716 5,905 5,152
EBIT 1 4,149 4,124 4,605 4,670 3,958 3,319 4,108 4,659 4,580 4,584 4,320 5,137 3,989 3,075
Operating Margin 14.89% 14.42% 15.53% 14.84% 12.47% 10.99% 14.79% 13.8% 13.22% 13.59% 12.7% 14.34% 11.42% 9.32%
Earnings before Tax (EBT) 1 3,480 3,375 4,436 3,850 3,430 2,697 4,080 4,802 4,710 -4,908 3,334 3,204 4,099 2,164
Net income 1 2,482 2,339 3,065 2,577 2,219 1,726 1,925 2,604 2,726 -4,283 1,499 2,574 2,450 2,243
Net margin 8.91% 8.18% 10.34% 8.19% 6.99% 5.72% 6.93% 7.72% 7.87% -12.7% 4.41% 7.19% 7.02% 6.8%
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/12/21 5/28/21 8/13/21 11/12/21 2/11/22 5/27/22 8/10/22 11/11/22 2/10/23 5/19/23 8/11/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 29,405 33,753 31,187 25,505 31,575 19,844 - -
Net Cash position 1 - - - - - - 3,080 11,304
Leverage (Debt/EBITDA) 1.639 x 1.988 x 1.496 x 1.099 x 1.386 x 1.542 x - -
Free Cash Flow 1 870 4,610 3,565 3,185 176 20,118 6,472 9,512
ROE (net income / shareholders' equity) 15.4% 12.9% 14.3% 12.3% 6.79% 1.45% 10.5% 12%
ROA (Net income/ Total Assets) 6.68% 5.38% 6.2% 6.08% - - - -
Assets 1 133,500 144,227 156,483 163,434 - - - -
Book Value Per Share 2 212.0 215.0 250.0 322.0 336.0 374.0 423.0 474.0
Cash Flow per Share 2 46.90 49.30 40.10 39.30 22.20 63.90 33.40 41.20
Capex 1 12,372 9,314 7,748 7,901 6,078 6,667 7,000 7,333
Capex / Sales 12.54% 8.75% 7.08% 6.4% 4.68% 5.49% 4.99% 4.69%
Announcement Date 5/29/19 6/26/20 5/28/21 5/27/22 5/19/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Glenmark Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1,079 INR
Average target price
962.8 INR
Spread / Average Target
-10.80%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
GLENMARK PHARMACEUTICALS LIMITED Stock Glenmark Pharmaceuticals Limited
+26.39% 3.65B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GLENMARK Stock
  4. Financials Glenmark Pharmaceuticals Limited